Second-generation recombinant factor VIII and inhibitor risk: Interpretation of RODIN study findings and implications for patients with haemophilia A

Haemophilia

Volumn 20, Issue 2, 2014, Pages

  Van der Bom, J G ^a,b   Gouw, S C ^c   Rosendaal, F R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SANQUIN RESEARCH   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FACTOR VIII; HEMOPHILIA A; HUMANS; ISOANTIBODIES; RECOMBINANT PROTEINS;

EID: 84894045169     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12342     Document Type: Letter

References (10)

1. Gouw SC, van der Bom JG, Ljung R et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368: 231-9.
2. Kessler CM, Iorio A. The Rodin (Research Of Determinants of INhibitor Development among PUPs with haemophilia) study: the clinical conundrum from the perspective of haemophilia treaters. Haemophilia 2013; 19: 351-4.
3. Franchini M, Mengoli C. RODIN and the pitfalls of observational studies. Haemophilia 2013; 19: e315-6.
4. Rosendaal FR, Nieuwenhuis HK, van den Berg HM et al. A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group. Blood 1993; 81: 2180-6.
5. Vandenbroucke JP, Psaty BM. Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects. JAMA 2008; 300: 2417-9.
6. Concato J. Study Design and "Evidence" in Patient-oriented Research. Am J Respir Crit Care Med 2013; 187: 1167-72.
7. Ter Avest PC, Fischer K, Mancuso ME et al. Risk stratification for inhibitor development at first treatment for severe hemophilia A: a tool for clinical practice. J Thromb Haemost 2008; 6: 2048-54.
8. Hernán MA, Robins JM. Estimating causal effects from epidemiological data. J Epidemiol Community Health 2006; 60: 578-86.
9. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology 2007; 18: 800-4.
10. Pahl S, Pavlova A, Driesen J, Müller J, Pötzsch B, Oldenburg J. In vitro characterization of recombinant factor VIII concentrates reveals significant differences in protein content, activity and thrombin activation profile. Haemophilia 2013; 19: 392-8.